In the News
LATEST
2021
Jan 6, 2022
Verily links up with Sosei Heptares for GPCR drug discovery
Jan 6, 2022
Sosei Heptares and Verily to collaborate on immune-mediated disease treatments
Jan 6, 2022
Sosei and Verily partner on GPCRs; ObsEva touts PhIII data in endometriosis pain - by Paul Schloesser
Nov 22, 2021
Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets - Biotech Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets - by Ben Adams
Nov 22, 2021
Bouncing back from a PhII flop in schizophrenia, Neurocrine steers into the busy M4/M1 pathway with a $100M cash deal - by John Carroll
Nov 22, 2021
Sosei finds second partner for muscarinic neurology assets in Neurocrine - by Stephen Hansen
Nov 22, 2021
Sosei, Neurocrine ink $2.6B neuropsychiatric collaboration - by Nuala Moran
LATEST
2021